Cytek Biosciences Inc
NASDAQ:CTKB

Watchlist Manager
Cytek Biosciences Inc Logo
Cytek Biosciences Inc
NASDAQ:CTKB
Watchlist
Price: 4.61 USD
Market Cap: $592.6m

Cytek Biosciences Inc
Depreciation & Amortization

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cytek Biosciences Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Cytek Biosciences Inc
NASDAQ:CTKB
Depreciation & Amortization
$7.6m
CAGR 3-Years
45%
CAGR 5-Years
66%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Depreciation & Amortization
$2.8B
CAGR 3-Years
-6%
CAGR 5-Years
4%
CAGR 10-Years
5%
Danaher Corp
NYSE:DHR
Depreciation & Amortization
$2.4B
CAGR 3-Years
3%
CAGR 5-Years
7%
CAGR 10-Years
11%
Waters Corp
NYSE:WAT
Depreciation & Amortization
$206.2m
CAGR 3-Years
17%
CAGR 5-Years
10%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Depreciation & Amortization
$283m
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
1%
IQVIA Holdings Inc
NYSE:IQV
Depreciation & Amortization
$1.1B
CAGR 3-Years
0%
CAGR 5-Years
-2%
CAGR 10-Years
25%
No Stocks Found

Cytek Biosciences Inc
Glance View

Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 496 full-time employees. The company went IPO on 2021-07-23. The firm offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). The Company’s FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide an integrated suite of solutions for its customers. The firm has sold and deployed over 1,000 instruments, primarily comprised of its Aurora and Northern Lights systems to customers around the world, including the pharmaceutical companies, over 150 biopharma companies, academic research centers, and clinical research organizations (CROs).

CTKB Intrinsic Value
4.08 USD
Overvaluation 11%
Intrinsic Value
Price $4.61

See Also

What is Cytek Biosciences Inc's Depreciation & Amortization?
Depreciation & Amortization
7.6m USD

Based on the financial report for Dec 31, 2025, Cytek Biosciences Inc's Depreciation & Amortization amounts to 7.6m USD.

What is Cytek Biosciences Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
66%

Over the last year, the Depreciation & Amortization growth was 5%. The average annual Depreciation & Amortization growth rates for Cytek Biosciences Inc have been 45% over the past three years , 66% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett